[SCHEDULE 13G/A] Aclaris Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

On 22 Jul 2025, MillerKnoll (MLKN) General Counsel Jacqueline Hourigan Rice converted 32,018 restricted stock units into common shares at a $0 exercise price (Code M). To cover withholding taxes (Code F), 14,488.129 of those shares were automatically sold at $19.50, resulting in a net increase of 17,529.871 shares.

Following the transactions, Rice directly owns 46,350.1981 MLKN shares versus 28,820.3271 prior to the filing, and still holds 98,747 unvested RSUs (51,699 cliff-vesting FY-24 bonus grant and 47,048 under a three-year schedule). The activity stems from incentive-plan elections rather than open-market trading, and no Rule 10b5-1 trading plan is referenced.

The filing signals continued equity alignment by a senior officer but is largely routine compensation-related and does not, by itself, alter MillerKnoll’s fundamental outlook.

Positive

• Insider net share accumulation: Rice’s direct holdings rose by ~61%, indicating increased alignment with shareholder interests.
• Equity in lieu of cash bonus: Executive elected RSUs over cash, strengthening pay-for-performance incentives.

Negative

• Share disposition: 14,488 shares were sold (withheld) at $19.50, modestly adding to market float, though motivated by taxes.

Insights

Securities Analyst

TL;DR: Routine RSU vesting; officer’s net share balance up ~61%, no open-market buying.

The filing shows Rice converting RSUs and withholding shares for taxes, a standard executive action. The net addition of 17.5k shares raises her direct stake to 46.3k, improving alignment with shareholders. Because the stock sales were compulsory for tax, they do not imply bearish sentiment. Retention of nearly 99k RSUs suggests further equity upside exposure. Market impact is minimal; no cash proceeds or strategic signals emerge.

Corporate Governance Expert

TL;DR: Compensation election converted cash bonus to equity, enhancing pay-for-performance linkage.

Rice chose RSUs instead of a cash bonus, reinforcing MillerKnoll’s long-term incentive philosophy. The cliff-vesting structure (1-year) and separate 3-year vesting schedule balance retention and motivation. Automatic sale for taxes adheres to best-practice compliance under Rule 16b-3. Overall governance view remains positive, but the event is not financially material to the company.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Aclaris Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

00461U105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00461U105

1

Names of Reporting Persons

Millennium Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,837,380.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,837,380.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,837,380.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 00461U105

1

Names of Reporting Persons

Millennium Group Management LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,837,380.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,837,380.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,837,380.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No. 00461U105

1

Names of Reporting Persons

Israel A. Englander

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,837,380.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,837,380.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,837,380.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aclaris Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 701 Lee Road, Suite 103, Wayne, Pennsylvania 19087
Item 2.
(a)	Name of person filing: Millennium Management LLC Millennium Group Management LLC Israel A. Englander
(b)	Address or principal business office or, if none, residence: Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022
(c)	Citizenship: Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States
(d)	Title of class of securities: Common Stock, par value $0.00001 per share
(e)	CUSIP No.: 00461U105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See response to Item 9 on each cover page.
(b)	Percent of class: See response to Item 11 on each cover page.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See response to Item 5 on each cover page.
	(ii) Shared power to vote or to direct the vote: See response to Item 6 on each cover page.
	(iii) Sole power to dispose or to direct the disposition of: See response to Item 7 on each cover page.
	(iv) Shared power to dispose or to direct the disposition of: See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group. See Exhibit I
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Millennium Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/23/2025

Millennium Group Management LLC

Signature:	/s/ Gil Raviv
Name/Title:	Gil Raviv, Global General Counsel
Date:	07/23/2025

Israel A. Englander

Signature:	/s/ Israel A. Englander
Name/Title:	Israel A. Englander
Date:	07/23/2025

Exhibit Information

Exhibit I: Joint Filing Agreement, dated as of July 23, 2025, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.

FAQ

How many MillerKnoll shares does Jacqueline Rice now own?

After the 22 Jul 2025 transactions, she directly owns 46,350.1981 MLKN shares.

What was the size of the RSU conversion in the July 2025 Form 4?

Rice converted 32,018 RSUs into common shares at a $0 exercise price.

Were the shares sold on the open market?

No discretionary sales occurred; 14,488 shares were automatically withheld at $19.50 solely to cover taxes.

Does the filing mention a 10b5-1 trading plan?

The Form 4 does not reference any Rule 10b5-1 trading plan.

Why does Rice still hold unvested RSUs after this transaction?

She retains 98,747 RSUs from a fiscal-2024 bonus grant and a separate three-year award that continue to vest over time.